Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

°©»ó¼±¾Ï¿¡ ÀÇÇÑ ¸²ÇÁÀý ÀüÀÌÀÇ CT Áø´Ü Lymph Node Metastases in Thyroid Carcinomas: CT Diagnosis

´ëÇѹæ»ç¼±ÀÇÇÐȸÁö 2001³â 45±Ç 6È£ p.581 ~ 588
¼Ò¼Ó »ó¼¼Á¤º¸
ÁÖÁö¼±/Ji Seon Joo ±èÇüÁø/°­°æÁø/Á¶¿µ±¹/ÀÓ¸í°ü/¼­Ã¢ÇØ/Hyung Jin Kim/Kyung Jin Kang/Young Kuk Cho/Myung Kwan Lim/Chang Hae Suh

Abstract

¸ñÀû:°©»ó¼±¾ÏÀÇ ÀÏÂ÷ ¹× ÀÌÂ÷ ¸²ÇÁÀý ÀüÀÌ¿¡ ´ëÇÑ CTÀÇ Áø´ÜÀû °¡Ä¡¸¦ Æò°¡ÇÏ°í,°©»ó¼±¾Ï
¿¡ ÀÇÇÑ ¸²ÇÁÀý ÀüÀÌÀÇ ´Ù¾çÇÑ CT ¼Ò°ßÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
´ë»ó°ú ¹æ¹ý:°©»ó¼±¾ÏÀ¸·Î °©»ó¼±ÀýÁ¦¼ú ¹× °æºÎû¼Ò¼úÀÌ ½ÃÇàµÈ ȯÀÚ Áß ¼ö¼ú Àü CT¸¦ ½ÃÇà
ÇÑ 59¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù.59¸í ¸ðµÎ¿¡¼­ ÀÏÂ÷ ¸²ÇÁÀý (Level VI)À» Á¦°ÅÇÏ´Â Áß¾ÓºÎû¼Ò¼ú
ÀÌ ½ÃÇàµÇ¾ú°í,21¸í¿¡¼­´Â ÃÑ 136 levelÀÇ ÀÌÂ÷ ¸²ÇÁÀý (Level II-V)À» Á¦°ÅÇÏ´Â ÃøºÎû¼Ò¼ú
ÀÌ º´ÇàµÇ¾ú´Ù.CT»ó ±âÁØÄ¡ ÀÌ»óÀÇ Å©±â,±ÕÁúÇÏ°í ³ôÀº Á¶¿µÁõ°­,¼®È¸È­,³¶¼º ¶Ç´Â ±«»ç¼º
º¯È­¸¦ º¸ÀÌ´Â °æ¿ì ¸²ÇÁÀý ÀüÀÌ°¡ ÀÖ´Â °ÍÀ¸·Î ÆÇÁ¤ÇÏ¿´´Ù.ÀÌ¿Í °°ÀÌ ºÐ¼®ÇÑ CT ¼Ò°ßÀ» Á¶
Á÷ÇÐÀû ¼Ò°ß°ú ºñ±³ÇÏ¿© ÀÏÂ÷ ¹× ÀÌÂ÷ ¸²ÇÁÀý ÀüÀÌ¿¡ À־ CTÀÇ Áø´Ü´ÉÀ» Æò°¡ÇÏ¿´°í,¸²ÇÁ
Àý ÀüÀÌÀÇ Áø´Ü¿¡ À¯¿ëÇÑ CT ¼Ò°ßÀ» ¾Ë¾Æº¸¾Ò´Ù.
°á°ú:59¸íÀÇ °©»ó¼±¾Ï ȯÀÚ Áß Á¶Á÷ÇÐÀûÀ¸·Î °æºÎ ¸²ÇÁÀý ÀüÀÌ´Â 31¸í (53%)¿¡¼­ Áø´ÜµÇ¾ú
À¸¸ç ÀÌ Áß ÀÏÂ÷ ¸²ÇÁÀýÀº 59¸í Áß 30¸í,ÀÌÂ÷ ¸²ÇÁÀýÀº 136 level Áß 44 level¿¡¼­ ÀüÀÌ°¡ °ü
ÂûµÇ¾ú´Ù.ÀÏÂ÷¿Í ÀÌÂ÷ ¸²ÇÁÀý ÀüÀÌ¿¡ ´ëÇÑ CTÀÇ ¹Î°¨µµ,ƯÀ̵µ,¾ç¼º¿¹Ãøµµ,À½¼º¿¹Ãøµµ ¹×
Á¤È®µµ´Â °¢°¢ 27%¿Í 93%,100%¿Í 93%,100%¿Í 87%,57%¿Í 97%,±×¸®°í 63%¿Í 93%
À̾ú´Ù.CT»ó ±âÁØÄ¡ ÀÌ»óÀÇ Å©±â (n=19),³¶¼º ¶Ç´Â ±«»ç¼º º¯È­ (n=14),¼®È¸È­ (n=8)ÀÇ
¼Ò°ß Áß ÇÑ °³ ÀÌ»óÀÇ ¼Ò°ßÀ» º¸ÀÌ´Â ÀÌÂ÷ ¸²ÇÁÀý¿¡¼­´Â Á¶Á÷°Ë»ç»ó ¸ðµÎ ÀüÀÌ°¡ ¹ß°ßµÇ¾úÀ¸
³ª,CT»ó Á¶¿µÁõ°­¸¸À» º¸ÀÎ 25 levelÀÇ ÀÌÂ÷ ¸²ÇÁÀý Áß 6 level (24%)¿¡¼­´Â Á¶Á÷ÇÐÀû ÀüÀÌ
¼Ò°ß ¾øÀÌ ¹ÝÀÀ¼º ¸²ÇÁÀý·Î Áø´ÜµÇ¾ú´Ù.
°á·Ð:°©»ó¼±¾ÏÀÇ °æºÎ ¸²ÇÁÀý ÀüÀÌÀÇ Æò°¡¿¡ À־ CTÀÇ ¹Î°¨µµ´Â ÀÏÂ÷ ¸²ÇÁÀý¿¡¼­´Â ¸Å¿ì
³·¾ÒÀ¸³ª ÀÌÂ÷ ¸²ÇÁÀý¿¡¼­´Â ºñ±³Àû ³ô¾Ò´Ù.±âÁØÄ¡ ÀÌ»óÀÇ Å©±â,¼®È¸È­ ¹× ³¶¼ºº¯È­´Â °©»ó
¼±¾ÏÀÇ ¸²ÇÁÀý ÀüÀ̸¦ ¿¹ÃøÇϴµ¥ ¸Å¿ì À¯¿ëÇÑ ÁöÇ¥·Î »ý°¢µÈ´Ù.

Purpose: To determine the usefulness of CT for diagnosing metastases to primary and secondary echelon
lymph nodes (LNs) and to investigate various CT findings of metastatic LNs in thyroid carcinomas.
Materials and Methods: We retrospectively reviewed the CT and histologic findings in 59 patients with thyroid
carcinomas who had undergone thyroidectomy and neck dissection. Primary echelon LNs (Level VI) were re-moved
by central neck dissection in all patients, and in 21, a total of 136 levels of secondary echelon LNs
(Level II-V) were excised away by lateral neck dissection. CT criteria of metastatic LNs included large size, sig-nificant
homogeneous enhancement, calcification, and cystic change. We evaluated the ability of CT to detect
primary and secondary echelon LN metastasis and tried to determine which CT features were useful for the
diagnosis of LN metastasis.
Results: Histologically, LN metastasis was found in 31 (53%) of 59 patients, including 30 with metastasis to
primary echelon LNs. Of the 136 levels of secondary echelon LNs resected in 21 patients, 44 were found at his-tology
to harbor metastatic foci. The sensitivities, specificities, positive and negative predictive values, and ac-curacies
of CT in the diagnosis of metastasis to primary and secondary echelon LNs, respectively, were 27%
and 93%, 100% and 93%, 100% and 87%, 57% and 97%, and 63% and 93%. While all secondary echelon LNs
with at least one of the following CT criteria -large size (n=19), cystic or necrotic change (n=14), or calcifica-tions
(n=8)-were histologically proven to be metastatic, six (24%) of 25 such LNs with a sole sign of signifi-cant
enhancement at CT were found to be due to reactive lymphadenopathy.
Conclusion: Although CT was unable to detect metastasis to primary echelon LNs, it was useful in the detec-tion
of secondary echelon LN involvement. Large size, cystic change, and calcification are considered highly
reliable signs of metastatic LNs.

Å°¿öµå

Lymphatic system; CT; Thyroid; CT; Thyroid; neoplasms;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS